The Aprea Therapeutics Team, along with Dr. Simpkins, Perelman School of Medicine and Dr. Yap, University of Texas discuss the Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways: Crucial Targets in Oncology & Tumor Suppression in a virtual meeting to be held on October 31 at 11 am. Webcast Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on APRE:
- Aprea Therapeutics to host investor meeting
- Aprea Therapeutics presents initial clinical data on ATRi, ATRN-119
- Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio
- Aprea Therapeutics Announces Two Posters at the Upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Aprea Therapeutics announces preclinical data on its ATRN-1051 candidate